Pacira Reports Record Margins, Strong Q1 Sales Amidst Proxy Fight
PCRX sits 22% above its 52-week low of $18.8.
Summary
Pacira BioSciences reported strong first-quarter 2026 product sales, including $143.3 million for EXPAREL, $26.8 million for ZILRETTA, and $6.2 million for iovera°, alongside achieving record gross margins. This positive financial update provides specific figures following a May 5th DEFA14A filing that broadly mentioned strong Q1 results. The company remains embroiled in an ongoing proxy contest with activist investor DOMA Perpetual Capital Management, which has nominated three director candidates, a situation that has been extensively detailed in multiple SEC filings since March. Strong financial performance could strengthen management's hand in the proxy battle ahead of the critical June 9th annual meeting. The outcome of the proxy contest at the annual meeting will be a key event to watch.
At the time of this announcement, PCRX was trading at $23.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $904.7M. The 52-week trading range was $18.80 to $27.64. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.